Cargando…

Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer

Previous research evaluating the use of adjuvant endocrine therapy among postmenopausal breast cancer patients showed with 15–50% wide ranges of non-adherence rates. We evaluated this issue by analysing an unselected study group comprising of 325 postmenopausal women, diagnosed from 1997 to 2003 wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Güth, U, Huang, D J, Schötzau, A, Zanetti-Dällenbach, R, Holzgreve, W, Bitzer, J, Wight, E
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527804/ https://www.ncbi.nlm.nih.gov/pubmed/18665168 http://dx.doi.org/10.1038/sj.bjc.6604525

Ejemplares similares

The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial
por: Gnant, M, et al.
Publicado: (2013)

Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile?
por: Duric, V M, et al.
Publicado: (2005)

Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience
por: Vetter, Marcus, et al.
Publicado: (2017)

Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer
por: Ribi, K, et al.
Publicado: (2012)

Comparison of gene expression profiles in core biopsies and corresponding surgical breast cancer samples
por: Zanetti-Dällenbach, Rosanna, et al.
Publicado: (2006)

Surgery Should Complement Endocrine Therapy for Elderly Postmenopausal Women with Hormone Receptor-Positive Early-Stage Breast Cancer
por: Nguyen, Olivier, et al.
Publicado: (2012)

Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids
por: Francini, G, et al.
Publicado: (2006)

Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index
por: Sendur, M A N, et al.
Publicado: (2012)

Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update
por: Mokbel, Ramia, et al.
Publicado: (2006)

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials
por: Ferretti, G, et al.
Publicado: (2006)

The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis
por: Engels, C. C., et al.
Publicado: (2015)

Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature
por: Opdam, M., et al.
Publicado: (2022)

AGR2 Predicts Tamoxifen Resistance in Postmenopausal Breast Cancer Patients
por: Hrstka, Roman, et al.
Publicado: (2013)

Estimated enterolignans, lignan-rich foods, and fibre in relation to survival after postmenopausal breast cancer
por: Buck, K, et al.
Publicado: (2011)

Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer
por: Kümmel, S, et al.
Publicado: (2006)

Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients
por: Lundin, K B, et al.
Publicado: (2011)

Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer
por: Pfeiler, G, et al.
Publicado: (2013)

Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota
por: Goedert, James J, et al.
Publicado: (2018)

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
por: Sestak, Ivana, et al.
Publicado: (2019)

Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer
por: Lemij, Annelieke A., et al.
Publicado: (2022)

Adjuvant ovarian function suppression and cognitive function in women with breast cancer
por: Phillips, Kelly-Anne, et al.
Publicado: (2016)

Evaluation of Acute Locoregional Toxicity in Patients with Breast Cancer Treated with Adjuvant Radiotherapy in Combination with Pazopanib
por: Goyal, Sharad, et al.
Publicado: (2012)

Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors
por: Kohler, Corina, et al.
Publicado: (2009)

Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial
por: Barnadas, A, et al.
Publicado: (2009)

Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry
por: Inwald, E. C., et al.
Publicado: (2015)

Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines
por: Berruti, A, et al.
Publicado: (2005)

Evaluation of Diabetic Patients with Breast Cancer Treated with Metformin during Adjuvant Radiotherapy
por: Ferro, Adam, et al.
Publicado: (2013)

Meibomian Gland Dysfunction: Endocrine Aspects
por: Sahin, Ozlem G., et al.
Publicado: (2011)

Timing of radiotherapy in breast-conserving therapy: a large prospective cohort study of node-negative breast cancer patients without adjuvant systemic therapy
por: Jobsen, J J, et al.
Publicado: (2013)

The current landscape of European registries for rare endocrine conditions
por: Ali, S R, et al.
Publicado: (2018)

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer
por: Slamon, Dennis J., et al.
Publicado: (2023)

Status of adjuvant endocrine therapy for breast cancer
por: Schiavon, Gaia, et al.
Publicado: (2014)

Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder
por: Hafeez, S, et al.
Publicado: (2015)

The Metabolic Syndrome among Postmenopausal Women in Gorgan
por: Marjani, Abdoljalal, et al.
Publicado: (2012)

Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial
por: Pfeiler, G, et al.
Publicado: (2013)

Potential markers of preeclampsia – a review
por: Grill, Simon, et al.
Publicado: (2009)

The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients
por: Lambertini, Matteo, et al.
Publicado: (2016)

The Type of Fat Ingested at Breakfast Influences the Plasma Lipid Profile of Postmenopausal Women
por: Morillas-Ruiz, J. M., et al.
Publicado: (2014)

Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy
por: Hannemann, J, et al.
Publicado: (2006)

Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy
por: Yun, J, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_e5k63r8f0657df0bamhg68h2dp